On July 31, LEADS BIOLABS-B rose 5.11% in regular trading, trading at HK$52.9/share, with turnover of HK$37.318 million.

On the news front, the company announced on July 30 that its core drug Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has completed full enrollment of all 70 patients in its Phase II clinical study for first-line treatment of advanced biliary tract cancer. The study entered its expansion phase in April based on favorable safety data and better-than-expected efficacy results, and rapidly completed enrollment thereafter, demonstrating efficient clinical execution.

This milestone reinforces Opamtistomig's breakthrough potential in immunologically cold tumors. The drug had previously been granted Priority Review status by China's NMPA for extrapulmonary neuroendocrine carcinoma, formally locking in its commercialization timeline. If final results are positive, Opamtistomig could become the first PD-L1/4-1BB bispecific antibody approved globally for cholangiocarcinoma.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)